华仁药业8月27日获融资买入2001.72万元，融资余额2.40亿元

Core Viewpoint - Hua Ren Pharmaceutical experienced a decline of 4.96% in stock price on August 27, with a trading volume of 174 million yuan, indicating potential market concerns regarding the company's performance and investor sentiment [1]. Financing Summary - On August 27, Hua Ren Pharmaceutical had a financing buy-in amount of 20.02 million yuan and a financing repayment of 20.01 million yuan, resulting in a net financing buy of -1,262 yuan [1]. - The total financing and securities balance for Hua Ren Pharmaceutical as of August 27 was 240 million yuan, which accounts for 5.88% of its circulating market value, indicating a relatively high level compared to the past year [1]. - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1]. Business Performance - As of August 20, the number of shareholders for Hua Ren Pharmaceutical was 41,000, a decrease of 1.20% from the previous period, while the average circulating shares per person increased by 1.22% to 28,801 shares [2]. - For the first half of 2025, Hua Ren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2]. Dividend Information - Since its A-share listing, Hua Ren Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3].